Evaluation of the effect of bosentan treatment on proinflammatory cytokine serum levels in patients affected by systemic sclerosis

International Journal of Immunopathology and Pharmacology

Volumn 24, Issue 1, 2011, Pages 261-264

  Bellisai, F ^a   Morozzi, G ^a   Scaccia, F ^a   Chellini, F ^a   Simpatico, A ^a   Pecetti, G ^b   Galeazzi, Mauro ^a  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

^b Actelion Pharmaceuticals Italia   (Italy)

Author keywords

Bosentan; Cytokines; Endothelin 1; Systemic sclerosis

Indexed keywords

BOSENTAN; CYTOKINE; ENDOTHELIN 1; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; ENDOTHELIN; METHOTREXATE; PREDNISONE; SULFONAMIDE;

ARTICLE; CLINICAL ARTICLE; DRUG SCREENING; HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; SYSTEMIC SCLEROSIS; THERAPY EFFECT; ULCER; ADULT; BLOOD VESSEL INJURY; DRUG EFFECT; FIBROSIS; FINGER ULCER; IMMUNOASSAY; IMMUNOFLUORESCENCE TEST; LOW DRUG DOSE; MIDDLE AGED; OUTCOME ASSESSMENT; SCLERODERMA; BLOOD; IMMUNOLOGY; LETTER;

CYTOKINES; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-6; INTERLEUKIN-8; MIDDLE AGED; SCLERODERMA, SYSTEMIC; SULFONAMIDES;

EID: 79957789715     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201102400134     Document Type: Article

References (14)

1. Korn JH. Pathogenesis of systemic sclerosis; arthritis and allied conditions, Koopman WJ editor. 2001 p. 1643-54.
2. Wigley FM, Flavahan NA. Raynaud's phenomenon. Rheum Dis Clin North Am 1996; 22:765-81. (Pubitemid 26396050)
3. Campbell PM, LeRoy EC. Pathogenesis of systemic sclerosis: a vascular hypothesis. Semin Arthritis Rheum 1975; 4:351-68.
4. Hummers LK, Wigley FM. Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma. Rheum Dis Clin North Am 2003; 29:293-313. (Pubitemid 36765122)
5. Korn JH, Mayes M, Matucci Cerinic M, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004; 50:3985-93. (Pubitemid 39643947)
6. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15:202-5. (Pubitemid 18073738)
7. Leask A. Signaling in fibrosis: targeting the TGF beta, Endothelin 1 and CCN2 axis in scleroderma. Front Biosci 2009; 1:115-22.
8. Sfikakis PP, Papamichael C, Stamatelopoulos KS, Tousoulis D, Fragiadaki KG, Katsichti P, Stefanadis C, Mavrikakis M. Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. Arthritis Rheum 2007; 56:1985-93. (Pubitemid 47110397)
9. Banerjee I, Fuseler JW, Intwala AR, Baudino TA. IL-6 loss causes ventricular dysfunction, fibrosis, reduced capillary density, and dramatically alters the cell populations of the developing and adult heart. Am J Physiol Heart Circ Physiol 2009; 296:1694-704.
10. Kadono T, Kikuchi K, Ihn H, Takehara K, Tamaki K. Increased production of interleukin 6 and interleukin 8 in scleroderma fibroblasts. J Rheumatol 1998; 25:296-301. (Pubitemid 28088258)
11. Coral-Alvarado P, Quintana G, Garces MF, Cepeda LA, Caminos JE, Rondon F, Iglesias-Gamarra A, Restrepo JF. Potential biomarkers for detecting pulmonary arterial hypertension in patients with systemic sclerosis. Rheumatol Int 2009; 29:1017-24.
12. Giacomelli R, Cipriani P, Fulminis A, Barattelli G, Matucci-Cerinic M, D'Alo S, Cifone G, Tonietti G. Circulating gamma/delta T lymphocytes from systemic sclerosis (SSc) patients display a T helper (Th) 1 polarization. Clin Exp Immunol 2001; 125:310-5. (Pubitemid 32758443)
13. Valentini G, Baroni A, Esposito K, Naclerio C, Buommino E, Farzati A, Cuomo G, Farzati B. Peripheral blood T lymphocytes from systemic sclerosis patients show both Th1 and Th2 activation. J Clin Immunol 2001; 21:210-7. (Pubitemid 32434308)
14. Molteni M, Della Bella S, Mascagni B, Bazzi S, Zulian C, Compasso S, Lessi M, Scorza R. Increased interferon-gamma (IFN-gamma) levels produced in vitro by alloactivated T lymphocytes in systemic sclerosis and Raynaud's phenomenon. Clin Exp Immunol 1999; 116:164-8. (Pubitemid 29170020)